{"created":"2021-03-01T06:18:41.807389+00:00","id":14271,"links":{},"metadata":{"_buckets":{"deposit":"060a9f71-3111-4557-8c75-59dd9d785cbe"},"_deposit":{"id":"14271","owners":[],"pid":{"revision_id":0,"type":"depid","value":"14271"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00014271","sets":["453:456","471:537:538:1061"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Effects of Two Immunosuppressants, Cyclosporin A and Mizoribime, and Angiotansin Converting Enzyme Inhibitor, Enalapril on Alport Model Mice"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2002-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"7","bibliographicPageEnd":"336","bibliographicPageStart":"324","bibliographicVolumeNumber":"116","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Effective pharmacotherapy in Alport syndrome has not yet been established. In this study, the efficiency of two immunosuppressants cyclosporin A (CyA) and mizoribine (MZR), and angiotensin converting enzyme inhibitor (ACEi), enalapril was examined using Col4 α 4 knockout mice as a model of this disease. CyA (10mg/kg/day), MZR (50mg/kg/day) and enalapril (18mg/kg/day) were administered everyday from three weeks of age. The CyA and enalapril treatments suppressed the elevation of proteinuria at 8 and 12 weeks of age and significantly inhibited the crescent formation at 12 weeks of age. The enalapril treatment could prolong the lives of Col4 α 4 mutant mice significantly, i.e, 26.3±6.2 weeks (mean±SD) of the treated mice vs. 18.3±3.9 weeks of the untreated control mice, whereas the CyA treatment failed to prolong the life span. Taken together, enalapril is considered to have a beneficial effect on the Alport model mice. This effect may be brought about by the improvement of renal hemodynamics and the suppression of an antiadhesion factor tenascin.","subitem_description_type":"Abstract"}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"伊東, 達雄"}],"nameIdentifiers":[{"nameIdentifier":"92635","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-07"}],"displaytype":"detail","filename":"KJ00000141921.pdf","filesize":[{"value":"2.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KJ00000141921.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/14271/files/KJ00000141921.pdf"},"version_id":"3e35d51a-8f09-4d4a-b5af-46172d50909f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Alport syndrome","subitem_subject_scheme":"Other"},{"subitem_subject":"knockout mice","subitem_subject_scheme":"Other"},{"subitem_subject":"cyclosporin A","subitem_subject_scheme":"Other"},{"subitem_subject":"angiotensin converting enzyme inhibitor","subitem_subject_scheme":"Other"},{"subitem_subject":"tenascin-C","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"アルポート症候群モデルマウスに対する薬物療法の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"アルポート症候群モデルマウスに対する薬物療法の検討"},{"subitem_title":"アルポート症候群モデルマウスに対する薬物療法の検討","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1061"],"pubdate":{"attribute_name":"公開日","attribute_value":"2007-05-10"},"publish_date":"2007-05-10","publish_status":"0","recid":"14271","relation_version_is_last":true,"title":["アルポート症候群モデルマウスに対する薬物療法の検討"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:46:20.125281+00:00"}